← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
AdaptHealth kept free cash flow positive and reduced debt, but revenue slipped and net income swung to a loss.
The read at a glance✓ Audited against SEC data
- Business mix — Healthcare-at-home equipment and servicesNote
- Revenue — Revenue -0.5% to $3.245BWatch
- Profitability — Net income swung to a $70.8M lossWatch
- Cash quality — Free cash flow -7.0% to $219.4MNote
- Balance sheet — Long-term debt -12.4% to $1.736BOK
- Insiders — 7 buys / 2 sells; $24.5M boughtOK
- Accounting — Altman-Z distress; EQ safeWatch
Business
AdaptHealth provides healthcare-at-home solutions including home medical equipment, medical supplies, and related services.
Where the revenue comes from
Fiscal 2025, as AdaptHealth Corp. reports it. History and quarterly detail are in the app.
- Sleep Health$1.4B
- Respiratory Health$691.2M
- Diabetes Health$592.4M
- Wellness at Home$583.1M
Leadership changes
From AdaptHealth Corp.'s own filings, the day they're filed.
- Diana L. Nole · director · appointmenteff. 2024-10-16
- Toby Scott Barnhart · Chief Operating Officer · appointmenteff. 2024-09-23
- Shaw Rietkerk · Chief Business Officer · departureeff. 2024-08-19
Latest filings
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-07-07
- 8-K · Company announcement2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AdaptHealth Corp., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.